Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.
Naohisa YoshidaYoshiaki KuriuJun IkedaMichihiro KudouToshihiko KirishimaTetsuya OkayamaKoji MiyagawaTsuyoshi TakagiMasayoshi NakanishiToshifumi DoiTakeshi IshikawaYoshito ItohEigo OtsujiPublished in: International journal of clinical oncology (2023)
A better OS and PFS comparing TAS-102 + Bev to TAS-102 for CRC was achieved in a large number of real-world patients.